B. Riley Predicts Stronger Earnings for Denali Therapeutics

Denali Therapeutics Inc. (NASDAQ:DNLI) – Equities research analysts at B. Riley upped their FY2025 earnings estimates for Denali Therapeutics in a report released on Thursday, November 13th. B. Riley analyst M. Mamtani now expects that the company will post earnings per share of ($3.02) for the year, up from their previous estimate of ($3.08). The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share. B. Riley also issued estimates for Denali Therapeutics’ FY2026 earnings at ($3.24) EPS, FY2027 earnings at ($2.48) EPS, FY2028 earnings at $1.98 EPS and FY2029 earnings at ($0.80) EPS.

Several other research analysts have also commented on DNLI. Weiss Ratings reissued a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Wednesday, October 8th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Denali Therapeutics in a research note on Monday, September 8th. Morgan Stanley dropped their target price on Denali Therapeutics from $33.00 to $30.00 and set an “overweight” rating on the stock in a report on Monday, August 18th. JPMorgan Chase & Co. upped their price target on Denali Therapeutics from $24.00 to $26.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. Finally, Stifel Nicolaus set a $37.00 price objective on shares of Denali Therapeutics in a research report on Monday. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $32.64.

Denali Therapeutics Stock Performance

NASDAQ:DNLI opened at $17.37 on Monday. The firm’s fifty day simple moving average is $15.29 and its 200 day simple moving average is $14.73. The company has a current ratio of 9.79, a quick ratio of 9.79 and a debt-to-equity ratio of 0.01. Denali Therapeutics has a twelve month low of $10.57 and a twelve month high of $26.18. The firm has a market capitalization of $2.55 billion, a price-to-earnings ratio of -5.97 and a beta of 1.39.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.02. During the same quarter in the previous year, the company earned ($0.63) EPS. The firm’s revenue was up .0% compared to the same quarter last year.

Hedge Funds Weigh In On Denali Therapeutics

Institutional investors have recently made changes to their positions in the business. Norges Bank purchased a new position in shares of Denali Therapeutics during the 2nd quarter valued at approximately $55,224,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Denali Therapeutics by 88.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,766,916 shares of the company’s stock valued at $91,996,000 after acquiring an additional 3,184,042 shares in the last quarter. Holocene Advisors LP boosted its stake in Denali Therapeutics by 677.8% during the 3rd quarter. Holocene Advisors LP now owns 3,135,712 shares of the company’s stock valued at $45,531,000 after acquiring an additional 2,732,540 shares during the last quarter. Wellington Management Group LLP grew its holdings in Denali Therapeutics by 15.9% during the 1st quarter. Wellington Management Group LLP now owns 11,409,598 shares of the company’s stock worth $155,113,000 after acquiring an additional 1,561,647 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Denali Therapeutics by 42.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,367,234 shares of the company’s stock worth $59,373,000 after purchasing an additional 1,308,619 shares during the last quarter. 92.92% of the stock is owned by institutional investors and hedge funds.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.